Core Viewpoint - A class action has been filed against uniQure N.V. for allegedly misleading investors regarding the FDA approval likelihood of its leading drug candidate, AMT-130 [1] Allegations - The complaint alleges that uniQure did not fully disclose that the design of its Pivotal Study was not fully approved by the FDA [1] - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [1] Impact of FDA Feedback - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from the Phase I/II studies of AMT-130 would be adequate for BLA submission [1] - Following this announcement, uniQure's stock price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1] Class Action Participation - Shareholders wishing to serve as lead plaintiffs must submit their papers by April 13, 2026 [1] - Participation in the case is not required to be eligible for recovery, and representation is on a contingency fee basis [1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the effectiveness of its gene therapy candidate AMT-130 and the likelihood of FDA approval [1][3]. Company Overview - uniQure, based in Amsterdam, specializes in developing and commercializing gene therapies for severe diseases, particularly focusing on Huntington's disease and other neurological disorders [2]. Legal Proceedings - The lawsuit pertains to investors who acquired uniQure securities between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiff appointments [2]. - The complaint claims that uniQure misrepresented the effectiveness of AMT-130 and the status of FDA agreement on study endpoints, which led to a significant stock price increase of nearly 250% from $13.66 to $47.50 per share shortly after the misleading statements [3]. Stock Performance - Following the revelation on November 3, 2025, that the FDA agreement on study design was not finalized, uniQure's stock plummeted over 49%, dropping from $67.69 to $34.29 per share [4].

Core Viewpoint - A class action lawsuit has been initiated against uniQure N.V. for alleged securities fraud, with a focus on misrepresentations regarding the company's drug candidate and regulatory approvals [1] Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1] - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [1] Group 2: Legal Representation - Rosen Law Firm, known for its success in securities class actions, is leading the lawsuit and encourages investors to select qualified counsel [1] - The firm has a strong track record, having achieved significant settlements for investors, including over $438 million in 2019 [1] - Investors can join the class action by contacting Rosen Law Firm through their website or phone [1] Group 3: Implications for Investors - The lawsuit alleges that when the true details about uniQure's business and operations were revealed, investors suffered damages [1] - A lead plaintiff is needed to represent the class, and interested parties must move the Court by April 13, 2026 [1] - Until the class is certified, investors are not represented by counsel unless they retain one [1]

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for securities law violations, specifically for making false and misleading statements regarding its FDA approval process and study design [1] Group 1: Lawsuit Details - The lawsuit pertains to violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is from September 24, 2025, to October 31, 2025, with a deadline for lead plaintiff appointments set for April 13, 2026 [1] - The complaint alleges that uniQure's public statements were materially misleading, particularly regarding the likelihood of delays in its Biologics License Application (BLA) with the FDA due to the need for additional studies [1] Group 2: Company Background - uniQure N.V. is a biotechnology company that focuses on gene therapies [1] - The company is listed on NASDAQ under the ticker symbol QURE [1] - The DJS Law Group, which is handling the lawsuit, specializes in securities class actions and corporate governance litigation [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. for the period between September 24, 2025, and October 31, 2025, due to alleged misrepresentations regarding the company's drug candidate and its regulatory approval status [1]. Group 1: Lawsuit Details - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline, which led to investors suffering damages when the true information became public [5]. - Investors who purchased uniQure shares during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - To join the class action, interested parties can visit the provided link or contact Phillip Kim, Esq. for more information. A lead plaintiff must file a motion by April 13, 2026 [3][6]. - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7].

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the efficacy and regulatory approval timeline of its gene therapy AMT-130 for Huntington's disease [1][2] Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, particularly Huntington's disease [1] - The leading drug candidate, AMT-130, aims to slow the progression of Huntington's disease, a fatal genetic disorder with no current cure [1] Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130 in March 2022 [1] - The FDA had previously agreed that the Pivotal Study results could be compared to an external historical dataset (Enroll-HD) instead of using a placebo comparator [1] - The company claimed that the results indicated a significant reduction in neurodegeneration, leading to expectations of accelerated approval from the FDA [1] Stock Performance and Fundraising - Following the announcement of positive topline results on September 24, 2025, uniQure's stock price surged nearly 250%, from $13.66 to $47.50 per share [1] - The company subsequently raised approximately $345 million through a public offering of over 5.7 million shares, despite uncertainties regarding AMT-130's approval timeline [2] Disclosure of Material Information - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II studies would support a BLA submission, leading to a stock price drop of over 49% [2] - The lawsuit alleges that uniQure misrepresented the approval status of the Pivotal Study and downplayed the likelihood of delays in the BLA submission process [2]

Core Viewpoint - A securities class action lawsuit has been filed against uniQure N.V. for failing to disclose material information regarding its drug candidate AMT-130, leading to significant stock price decline during the class period [1][3][4]. Group 1: Lawsuit Details - Investors have until April 13, 2026, to file lead plaintiff applications if they purchased shares between September 24, 2025, and October 31, 2025 [1]. - The lawsuit alleges that uniQure and certain executives violated federal securities laws by not disclosing critical information during the class period [3]. - The case is identified as Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124 [5]. Group 2: Company Performance and Impact - During the class period, uniQure indicated a high likelihood of receiving accelerated FDA approval for AMT-130, which was later contradicted by the FDA's assessment [4]. - Following the FDA's announcement on November 3, 2025, uniQure's stock price fell by $33.40, or over 49%, from $67.69 to $34.29 per share [4].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging misrepresentations related to the drug AMT-130 for Huntington's Disease treatment [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made false statements regarding the development of AMT-130, which is intended for treating Huntington's Disease [4]. - Investors who wish to serve as lead plaintiffs must file papers by April 13, 2026, and participation does not require serving as lead plaintiff [3]. Group 2: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since its establishment in 1993 and has represented both individual investors and large pension funds [5]. - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years [5].

Core Viewpoint - Investors in uniQure N.V. have the opportunity to lead a securities fraud lawsuit against the company due to alleged violations of the Securities Exchange Act of 1934, specifically related to misleading statements about FDA approval and BLA timelines [1] Group 1: Lawsuit Details - The Schall Law Firm is reminding investors of a class action lawsuit against uniQure N.V. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is defined as between September 24, 2025, and October 31, 2025, during which investors are encouraged to contact the firm before April 13, 2026 [1] - The lawsuit claims that uniQure made false and misleading statements regarding its ability to secure full FDA approval for its Pivotal Study and misrepresented the likelihood of delaying its BLA timeline [1] Group 2: Investor Impact - Investors who purchased uniQure's securities during the class period reportedly suffered damages when the truth about the company's misleading statements was revealed [1] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally, indicating a focus on protecting shareholder rights [1]

Core Viewpoint - A class action lawsuit has been filed against uniQURE N.V. on behalf of investors who acquired its securities during the specified class period from September 24, 2025, to October 31, 2025 [1] Group 1 - The law firm Kirby McInerney LLP is representing the investors in the class action lawsuit [1] - Investors who suffered losses on their uniQURE investments have until April 13, 2026, to request lead plaintiff appointment [1] - Courts do not consider lead plaintiff applications submitted after the deadline [1]